Delivery Order SPE2DB20D2104-SPE2DB25FNALT
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 10 mg capsules (100-count units) under a firm fixed price contract on September 12, 2025, with a ceiling value of $1,337.70 and ultimate completion date of September 15, 2025. This non-competitive delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor for federal medical procurement, leveraging the company's existing indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 50 mg capsules (100-count units) valued at $1,876.30 under a firm fixed price contract type. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-competitive delivery order executed against AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of Vyvanse 30 mg capsules (quantity 100) with a contract value of $1,163.08. This is a firm fixed price delivery order with an ultimate completion date of July 16, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,372.32 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 60 mg on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work is to...
- The Defense Logistics Agency awarded a $1,754.54 firm fixed price delivery order to AmerisourceBergen Drug Corp for Vyvanse 30 mg capsules (100 count) on July 14, 2025, with an ultimate completion date of July 15, 2025. This non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100-count units) on August 25, 2025, with a ceiling value of $1,781.07 and an ultimate completion date of August 26, 2025. This contract was awarded competitively with no set-aside designation and utilizes firm fixed-price pricing. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,927.86. The order was competitively awarded without set-aside designation and is scheduled for completion by July 31, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location and serve as the prime contractor on this delivery order, which...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Vyvanse 50 mg capsules (100 count) with a contract ceiling value of $4,076.22. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FNALTDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) valued at $3,100.35, with a firm fixed price structure and no set-aside designation. The award was issued on September 15, 2025, with an ultimate completion date of September 16, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery vehicle with DLA Troop Support Medical. This delivery order is executed under AmerisourceBergen's existing $999,999,999.00 indefinite delivery contract (SPE2DX) with DLA Troop Support Medical, running through December 2026. This prime vendor agreement enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs globally. Vyvanse, a prescription medication commonly used in treatment of attention deficit hyperactivity disorder, represents one component of the comprehensive pharmaceutical portfolio that AmerisourceBergen delivers through this vehicle to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 9/15/25 |